Primary lung cancer proton, primary lung cancer, early-stage
Conditions
Interventions
None listed
Sponsors
Sakurai Hideyuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)The patient's written consent to participate in the study has been obtained. 2)The patient's age at the time consent is obtained is at least 18 years old. 3) Performance status by Eastern Cooperative Oncology Group is 0-2. 4) Historically or clinically diagnosed primary lung cancer.
Exclusion criteria
Exclusion criteria: 1) Patients with serious complications (severe infection, heart failure, acute myocardial infarction, respiratory failure, liver failure, renal failure, acute cerebrovascular disease, poorly controlled diabetes). (2) Patients with active multiple cancers at the time of obtaining consent. Active overlapping cancers are defined as synchronous overlapping/multiple cancers and heterochronic overlapping/multiple cancers with a disease-free period of 5 years or less. However, this does not include stage 0 or stage I laryngeal cancer that has responded completely to radiotherapy. Also, a history of completely resected cancer with a 5-year relative survival rate equivalent to 95% or more. In principle, staging is based on the UICC-TNM 8th edition or equivalent. 3) Patients with refractory inflammatory disease in the irradiated area. 4) Patients with inflammatory diseases requiring systemic treatment. 5) Patients with severe dementia or other conditions that make it difficult to understand the treatment. (6) Other patients who are deemed inappropriate for this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The 3-year overall survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event rates, the 5-year overall survival rate, the 3-/5-year progression-free survival rates, the 3-/5-year local control rates | — |
Contacts
Public ContactMasatoshi Nakamura
University of Tsukuba Hospital
Outcome results
None listed